Key result
Commercial Triage BNP test fails to diagnose heart failure in dogs due to insufficient sensitivity.
Why the study?
Blood-based biomarker diagnostics, well-established for heart failure in humans, are increasingly needed for diagnosing and monitoring heart disease in dogs and cats.
Can blood-based biomarkers (cardiac troponin and natriuretic peptides) be used for the diagnosis and monitoring of heart failure in dogs and cats?
Observational (n=9)
No
Can blood-based biomarkers (cardiac troponin and natriuretic peptides) be used for the diagnosis and monitoring of heart failure in dogs and cats?
Highlights the emerging role of cardiac biomarkers like troponin and natriuretic peptides in diagnosing and monitoring heart failure in veterinary practice.
Caution against commercial human BNP kits in dogs; leaves open need for validated veterinary-specific assays.
Every doctor, one way or another, is faced with the problem of chronic heart failure (CHF) in animals [1]. Over 3 million dogs suffer from some form of acquired heart disease. In recent years, biomarkers, mainly cardiac troponin and natriuretic peptides, have become the main source of information for both diagnosis and monitoring of the human heart. Today, the need for diagnostics based on blood samples has become evident also when working with dogs and cats.
No takes yet. Share an insight, caveat, or question.
L.V. Annikova (2022) conducted an observational in Heart failure in dogs (n=9). Triage BNP test kit vs. Clinically healthy dogs was evaluated on BNP level measured by Triage BNP test. The commercial Triage BNP test kit is not suitable for diagnosing heart failure in dogs, as BNP levels in all tested animals were below the device's sensitivity threshold of 5 pg/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: